CD55 Monoclonal Antibody (MEM-118), FITC, Invitrogen™

Description

• CD55 (decay-accelerating factor, DAF) is a GPI-anchored membrane glycoprotein that protects autologous cells from classical and alternative pathway of complement cascade
• Bidirectional interactions between CD55 and CD97 are involved in T cell regulation and CD55 can regulate complement when bound to CD97
• In tumors, CD55 promotes neoangiogenesis, tumorigenesis, invasiveness and evasion of apoptosis
• CD55 is a 70 kDa glycoprotein (in erythrocytes) anchored in the membrane by glycosylphosphatidylinositol tail
• In other cells, the apparent molecular weight is somewhat larger for CD55 and has a substantial content of O-glycans
• CD55 binds to activated C4b or C3b complement fragments on the cell surface, preventing the assembly and accelerating the decay of both classical and alternative pathways
• CD55 carries the Cromer related blood group antigens
• Two alternatively spliced transcripts encoding CD55 have been identified, and the predominant transcript encodes a membrane-bound protein expressed on cells exposed to plasma component proteins but an alternatively spliced transcript produces a soluble protein present at much lower levels
• CD55 has been studied to have a role in prostate cancer growth and survival.